Arthritis

Latest

Lower Cartilage Degeneration With Weight Loss in OA

Lower Cartilage Degeneration With Weight Loss in OA

MRI was utilized to assessed cartilage degeneration in patients who lost weight over a 48-month period.

Dose-Dependent ACR20 Response Rates in RA With Peficitinib

Dose-Dependent ACR20 Response Rates in RA With Peficitinib

Use of the JAK inhibitor peficitinib in combination with certain csDMARDs results in a dose-dependent ACR20 response rate in patients with RA over 12 weeks.

Imaging Recommendations by EULAR for Symptomatic Osteoarthritis

Imaging Recommendations by EULAR for Symptomatic Osteoarthritis

The first evidence-based recommendations on the use of imaging in osteoarthritis clinical practice have been released by the European League Against Rheumatism.

FDA Approves Knee OA Treatment for 26 Weeks

FDA Approves Knee OA Treatment for 26 Weeks

The FDA has approved 26-week treatment efficacy claims for Zimmer Biomet's knee osteoarthritis product.

Can Tocilizumab Treat RA After Non-TNFi Failure?

Can Tocilizumab Treat RA After Non-TNFi Failure?

Better efficacy for tocilizumab versus abatacept and rituximab in patients with first non-TNFi failure.

Vitamin D May Not Benefit Knee Osteoarthritis

Vitamin D May Not Benefit Knee Osteoarthritis

Supplements didn't slow disease progression or ease pain, even in patients with low levels of vitamin D.

What is the Most Effective NSAID to Relieve Knee OA Pain?

What is the Most Effective NSAID to Relieve Knee OA Pain?

A team of researchers from Switzerland studied the efficacy of different formulations and doses of NSAIDs on osteoarthritis pain by conducting a network meta-analysis.

Can Obese Patients With Knee Osteoarthritis Benefit From A New Home-Based Device?

Can Obese Patients With Knee Osteoarthritis Benefit From A New Home-Based Device?

Biomechanical device tied to improvement in all gait parameters at three, 12 months.

Arthritis Patients: We Want Info About Multiple Drug Options

Arthritis Patients: We Want Info About Multiple Drug Options

Patients with inflammatory arthritis want to be informed about current, future treatment options.

Rituximab Retreatment At Clinical Relapse Cost-Effective In RA

Rituximab Retreatment At Clinical Relapse Cost-Effective In RA

At least as cost-effective as more intensive regimen in patients with longstanding RA.